\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesYesterday the Commission launched the public consultation on the past, present and future of the EU’s Horizon research and innovation programmes 2014-2027. With this consultation, the Commission is collecting input which will be used for:
The public consultation allows participants to:
The consultation will be closed in February 2023.
More information can be found in the news article of the Directorate-General for Research and Innovation of the European Commission. The online consultation can be accessed via EU Survey.
For any question related to the consultation, please contact RTD-PUBLIC-CONSULTATION-HORIZON@ec.europa.eu.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
